Description Usage Arguments Value Author(s) References See Also Examples

The PKPOP model is a variation of the PKLOGIT model which replaced AUCs (*z_j*) with AUC of the population (*z_{k,pop}*), where *z_{k,pop}* is the mean value of the logarithm of AUC at dose k, predicted by the hierarchical model:

*z_{i} \vert \boldsymbol{β}, ν \sim N ≤ft( β_0 + β_1 \log d_{i}, ν^{2} \right)*

where *\boldsymbol{β} = (β_0,β_1)* are the regression parameters and *ν* is the standard deviation.
and the logistic regression model:

*\mbox{logit}(p_T(z_{k,pop}, \boldsymbol{β})) = -β_3 + β_4 z_{k,pop}*

with a bivariate Uniform distribution as prior distribution for the parameters *\boldsymbol{β} = (β_3, β_4)*.

The default choices of the priors are:

*\boldsymbol{β} \vert ν \sim N(m, ν*beta0),*

*ν \sim Beta(1,1),*

*m = (-log(CL_{pop}), 1),*

where *Cl_{pop}* is the population clearance.

*β_3 \sim U(0, beta3mean),*

*β_4 \sim U(0, beta4mean)*

where default choices are *Cl_{pop} = 10*, beta0 = 10000, beta3mean = 10 and beta4mean = 5. Therefore, the default choices for model's priors are given by

*betapriors = c(Cl_{pop} = 10, beta0 = 10000, beta3mean = 10, beta4mean = 5)*

Finally, the PKPOP model has the following stopping rule in toxicity: if

*P(p_T(dose) > theta) > prob*

then, no dose is suggested and the trial is stopped.

1 2 3 |

`y` |
A binary vector of patient's toxicity outcomes; TRUE indicates a toxicity, FALSE otherwise. |

`doses` |
A vector with the doses panel. |

`x` |
A vector with the dose level assigned to the patients. |

`theta` |
The toxicity target. |

`prob` |
The threshold of the posterior probability of toxicity for the stopping rule; defaults to 0.9. |

`betapriors` |
A vector with the value for the prior distribution of the regression parameters in the model; defaults to betapriors = c( |

`options` |
A list with the Stan model's options; the number of chains, how many iterations for each chain and the number of warmup iterations; defaults to options = list(nchains = 4, niter = 4000, nadapt = 0.8). |

`auc` |
A vector with the computed AUC values of each patient for pktox, pkcrm, pklogit and pkpop; defaults to NULL. |

`deltaAUC` |
The difference between computed individual AUC and the AUC of the population at the same dose level (defined as an average); argument for pkcov; defaults to NULL. |

`p0` |
The skeleton of CRM for pkcrm; defaults to NULL (must be defined only in the PKCRM model). |

`L` |
The AUC threshold to be set before starting the trial for pklogit, pkcrm and pktox; defaults to NULL (must be defined only in the PKCRM model). |

`thetaL` |
A second threshold of AUC; must be defined only in the PKCRM model. |

`CI` |
A logical constant indicating the estimated 95% credible interval; defaults to TRUE. |

A list is returned, consisting of determination of the next recommended dose and estimations of the model. Objects generated by pkpop contain at least the following components:

`newDose` |
The next maximum tolerated dose (MTD); equals to "NA" if the trial has stopped before the end, according to the stopping rules. |

`pstim` |
The mean values of estimated probabilities of toxicity. |

`p_sum` |
The summary of the estimated probabilities of toxicity if CI = TRUE, otherwise is NULL. |

`parameters` |
The estimated model's parameters. |

Artemis Toumazi [email protected], Moreno Ursino [email protected], Sarah Zohar [email protected]

Ursino, M., et al, (2017) Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations, Biometrical Journal, <doi:10.1002/bimj.201600084>.

Toumazi, A., et al, (2018) dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials, Computer Methods and Programs in Biomedicine, <doi:10.1016/j.cmpb.2018.01.023>.

Patterson, S., Francis, S., Ireson, M., Webber, D., and Whitehead, J. (1999) A novel bayesian decision procedure for early-phase dose-finding studies. Journal of Biopharmaceutical Statistics, 9 (4), 583-597.

Whitehead, J., Patterson, S., Webber, D., Francis, S., and Zhou, Y. (2001) Easy-to-implement bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics, 2 (1), 47-61.

Whitehead, J., Zhou, Y., Hampson, L., Ledent, E., and Pereira, A. (2007) A bayesian approach for dose-escalation in a phase i clinical trial incorporating pharmacodynamic endpoints. Journal of Biopharmaceutical Statistics, 17 (6), 1117-1129.

`pklogit`

, `sim.data`

, `nsim`

, `nextDose`

1 2 3 4 5 6 7 8 9 10 11 | ```
## Not run:
doses <- c(12.59972,34.65492,44.69007,60.80685,83.68946,100.37111)
theta <- 0.2 # choice
options <- list(nchains = 2, niter = 4000, nadapt = 0.8)
AUCs <- c(0.43, 1.4, 5.98, 7.98, 11.90, 3.45)
x <- c(1,2,3,4,5,6)
y <- c(FALSE,FALSE,FALSE,FALSE,TRUE,FALSE)
res <- pkpop(y, AUCs, doses, x, theta, options = options)
## End(Not run)
``` |

dfpk documentation built on Nov. 9, 2018, 5:05 p.m.

Embedding an R snippet on your website

Add the following code to your website.

For more information on customizing the embed code, read Embedding Snippets.